Societal Preferences for Adjuvant Melanoma Health States: UK and Australia

BMC Cancer - United Kingdom
doi 10.1186/s12885-017-3673-y
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

What Matters Most?: Evidence-Based Findings of Health Dimensions Affecting the Societal Preferences for EQ-5D Health States

Cadernos de Saude Publica
MedicineEnvironmentalPublic HealthOccupational Health
2013English

Patient and Physician Preferences for Treating Adjuvant Melanoma: A Discrete Choice Experiment

Journal of Cancer Therapy
2017English

Preference-Based Utilities for Adjuvant Melanoma in the United Kingdom and Australia

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2016English

Are Preferences Over Health States Informed?

Health and Quality of Life Outcomes
MedicineEnvironmentalPublic HealthOccupational Health
2017English

Adjuvant Radiation for Malignant Melanoma

Kansas Journal of Medicine
2008English

Adjuvant Therapy: Melanoma

Journal of Skin Cancer
DermatologyOncology
2011English

Considering Adjuvant Therapy for Stage II Melanoma

Cancer
Cancer ResearchOncology
2019English

Societal Preferences for Funding Orphan Drugs in the UK: An Application of Value Based Pricing Using Discrete Choice Experiment Methods

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

Adjuvant and Neoadjuvant Treatment of Melanoma

Memo - Magazine of European Medical Oncology
OncologyHematology
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy